David A. Gerrish

**** ***** ******** ****. *** H*, North Olmsted, OH. 44070

Cell: 216-***-****

ac2viu@r.postjobfree.com

Research Qualifications

Advanced skills in synthesizing (5 mg to 200 g scale), isolation and characterizing novel organic compounds such as Triterpenes, Purines, Benzazepines, and Heterocyclic compounds

Experience with the following instrumentation:

High Performance Liquid Chromatography (HPLC)

Nuclear Magnetic Resonance Spectroscopy (NMR)

ESI Mass Spectroscopy

Gas Chromatography Mass Spectrometry (GC-MS)

Fourier Transform Infrared Spectroscopy (FT-IR)

Microwave, and Combiflash

Substantial experience with Suzuki, Heck, Sonogashira, Buchwald-Hartwig Coupling, and Stille reactions

Proficient with using: Scifinder, Beilstein, Word, Excel, and PowerPoint

General maintenance and repairs of HPLC and NMR instrumentation as needed

Professional Experience Summary

Athersys Inc. - Cleveland OH

Athersys, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutic products in various disease areas in the United States. Its clinical development programs are focused on treating inflammatory and immune disorders, neurological conditions, cardiovascular disease, and other conditions. The company is also involved in the development of pharmaceuticals to treat obesity, and related metabolic conditions, such as diabetes and neurological indications.

Medicinal Chemistry

Senior Research Associate January 2015-Current

Research Associate III May 2011-December 2014

Obesity Project

Performed twelve to fifteen step syntheses of small molecules for inhibiting 5-HT2C receptors in the central nervous system.

I played a critical role in designing and solving the challenges associated with scaling up 150 grams of material for toxicology studies.

Synthesized and characterized novel biological active 5-HT2C inhibitors which include core structures such as tricyclic and tetracyclic Benzazepine ring systems.

I play a critical role in designing small molecules with the use of molecular modeling and SAR data.

Performed chiral separation on all final compounds.

Myrexis Pharmaceuticals - Salt Lake City UT

Myrexis, Inc. (formerly Myriad Pharmaceuticals, Inc.) is a biotechnology company focused on discovering, developing, and commercializing novel therapies for the treatment of cancer. Their pipeline includes clinical and pre-clinical product candidates with distinct mechanisms of action and novel chemical structures that have the potential to be first-in-class and/or best-in-class therapeutics.

Medicinal Chemistry

Research Associate III July 2006 – March 2011

Research Associate II July 2004 - June2006

Oncology Projects

Synthesis of small molecules for inhibiting members of the Kinase family.

I played a critical role in designing small molecules with the use of molecular modeling and SAR data.

Synthesized numerous Kinase inhibitors which are very potent and efficacious in cell based assay.

Synthesized and characterized novel biological active compounds related to Topoisomerase II inhibition, which include core structures such as Purines, Pyrimidines, and Benzoxazole ring systems.

Anti-Viral Project

Played a critical role in advancing the project form HTS to lead optimization and beyond.

Independently conceived novel compounds and successfully executed SAR studies with the objective of improving in vitro potency and cell based anti-viral efficacy.

Integrated modifications to lead compounds to improve PK and ADME properties.

Designed synthetic routes for process scale.

Synthesized numerous anti-viral compounds which are very potent and efficacious in cell based assay.

My individual contributions as a medicinal chemist resulted in three compounds being designated as potential drug candidates, one of which was declared and IND and two back-up compounds.

University of Maryland, Baltimore County - Catonsville, MD

This UMBC laboratory specializes in the Sequence –and- Structure Specific DNA Binding Compounds. In particular, research is focused on identifying specific binders for complex DNA structures involved in gene regulation and cell division.

Masters Degree Research June 2001 – December 2004

Synthesized and characterized novel biological active compounds related to Topoisomerase II inhibition

Synthesized and characterized novel organic compounds related to Purine, Pyrimidines, and Benzoxazole Ring Systems

Utilize wet chemistry techniques, including but not limited to, column chromatography, MALDI-TOF MS, ESI-MS, HPLC, GC/MS, and NMR in the analysis of small organic compounds

Teaching Assistant September 2001 – May 2004

Provided instruction and assistance for multiple Organic Chemistry laboratory sessions

Participated in preparation of organic laboratory experiments

Provided Professor assistance in the area of grading classroom and laboratory assignments as well as exams

Education

University of Maryland – Baltimore, MD

M.S. – Organic Chemistry: December 2004

Thesis: Synthesis of UK-1 Analogs as Potential Topoisomerase II Inhibitors

Hood College – Frederick, MD

B.A. – Chemistry, May 2001

Hagerstown Junior College – Hagerstown, MD

A.A. – Biology, May 1999

United States Military

U.S. Army

101st Airborne Division

Fort Campbell, Kentucky

Patent Applications

1. Arranz Plaza, Esther; Yager, Kraig, M.; Gerrish, David, A.; Anderson, Mark, B.; Kim, In Chul; Kumar, Dange, Vijay. “Antiviral Compounds” WO/2007/002411.

2. Yager, Kraig, M.; Gerrish, David, A.; Kim, In Chul; Anderson, Mark, B. “Antiviral Compounds and Use Thereof” WO/2008/097341.

3. Yager, Kraig, M.; Kim, In Chul; Saunders, Michael; Gerrish, David, A.; Kumar, Dange, Vijay.; Anderson, Mark, B. “Antiviral Compounds and Use Thereof” WO/2008/127364.

4. Kumar, Dange, Vijay; Yager, Kraig, M.; Gerrish, David, A.; Hoarau, Christophe; Anderson, Mark, B. “Compounds and Therapeutic Use Thereof” WO/2009/073818.

5. Kumar, Dange, Vijay; McAlexander, Ian, A.; Bursavich, Matthew; Hoarau, Christophe; Slattum, Paul; Gerrish, David, A.; Lockman, Jeffrey, W.; Judd, Weston, R.; Saunders, Michael; Parker, Daniel, P.; Zigar, Daniel, Feodore; Kim, In, Chul; Willardsen, J., Adam; Yager, Kraig, M.; Shenderovich, Mark, D.; Williams, Brandi, L,; Tardif, Keith, D.; “Purine Derivatives Useful As Anti-Cancer Agents” WO/2010/111406.

6. Robarge, Mike; Harrington, John; Gerrish, David; Mecom, John. “Benzazepines As Serotonin 5-HT2c Receptor Ligands And Uses Thereof” WO/2014/100815A2.

Publications

1.Gerrish, David; Kim, In Chul;, Kumar, V. Dange; Austin, Harry; Garrus, Jennifer; Baichwal, Vijay; Saunders, Michael; Anderson, Mark, B; Carlson, Robert; Arranz-Plaza, Esther; and Yager, Kraig M. “Triterpene based compounds with potent anti-maturation activity against HIV-1”. Bioorganic and Medicinal Chemistry Letters 18 (2008) 6377–6380

2.Kumar, V. Dange; Hoarau, Christophe; Bursavich, Matthew; Slatum, Paul; Gerrish, David; Yager, Kraig; Saunders, Michael; Shenderovich, Mark; Roth, Bruce; McKinnon, Rena; Chan, Ashley; Cimbora, Daniel M.; Bradford, Chad; Reeves, Leslie; Patton, Scott; Papac, Damon I.; Williams, Brandi L.; Carlson, Robert O.; “Lead Optimization of Purine Based Orally Bioavailable Mps1 (TTK) inhibitors”. Bioorganic and Medicinal Chemistry Letters 18 (2012).

Contact this candidate